|View printer-friendly version|
|Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk|
The new lab-developed tests feature a 34-gene panel that includes several genes not widely found on existing cancer risk panels. Emerging evidence suggests that the presence of certain mutations of these genes may heighten an individual's likelihood of developing certain types of breast, ovarian, endometrial and other cancers.
"The Quest Vantage service combines the latest advances in laboratory diagnostic technology with unmatched convenience and simplicity," said
Nearly 1.7 million new cancer cases are expected to be diagnosed in 2016, and as many as 10% of those cancers will be the result of an inherited gene mutation. Insight into hereditary risk enables an individual to consider steps, such as more frequent screening, to potentially detect cancer in an earlier, more treatable stage.
Using next-generation sequencing and a proprietary bioinformatics platform, the new Quest Vantage services together aid the detection of genetic variants associated with inherited risk of 15 cancers, including breast, colorectal, pancreatic and renal. They are:
The tests only include genes meeting certain criteria, such as a two-fold increased cancer risk, association with a disease syndrome for which cancer may occur, and guideline support for genetic counseling. GIvantage and Qvantage panels, designed for patients with a limited subset of cancers in their family history, only include genes for which national guidelines provide medical management recommendations for pathogenic or likely pathogenic gene variants. In addition, each gene variant detected during testing is interpreted according to a rigorous process led by the company's medical experts.
Quest intends to share Quest Vantage variant data with ClinVar, an open variant database. The company also shares BRCA variant data with BRCA Share, a user group it co-founded with Inserm,
With the new offerings, the Quest Vantage menu includes approximately a dozen genetic test panels and single-gene test services, including several BRCAvantage® services for assessing risk of breast, ovarian and other cancers based on mutations of the BRCA1, BRCA2 and other genes. The number and composition of the Quest Vantage menu was determined based on counsel from oncologists, obstetricians, gynecologists, medical geneticists and genetic counselors.
The services also incorporate the breadth of Quest's national expertise and scale, which includes 2,300 patient service centers, broad health plan relationships and test ordering connectivity through nearly 600 EHR platforms.
In addition, Quest Vantage is designed to support the patient through the entire testing process, with access to third-party genetic counselors services and support for patients through prior authorization and health plan reimbursement. The company also provides financial assistance to qualified uninsured and underinsured patients. Patients may access test results through the company's myQuest™ patient app.
"These capabilities provide patients and physicians with access to the highest quality testing and robust support capabilities" said Dr. Fikry.
The company will showcase the new Quest Vantage offerings at the 2016 American Society of Clinical Oncology (
For more information on the Quest Vantage menu, visit www.QuestVantage.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quest-diagnostics-launches-three-genetic-test-panels-for-predicting-hereditary-cancer-risk-300275638.html